张兴旺，男,博士，副教授，硕士生导师。皖亳州市人，2005年7月毕业于安徽中医学院，药物制剂专业；2008年7月毕业于河南中医学院，药剂学专业；2013年7月毕业于复旦大学，药剂学专业，博士论文获得上海市研究生优秀论文成果奖（优博）。2008年8月– 2010年9月，先后任职于上海医药（集团）中央研究院与和记黄埔（上海）医药有限公司，从事药物制剂的研发工作。2013年8月– 2015年8月在暨南大学中药学博士后流动站工作。2015年9月至今就职于暨南大学药学院，任副教授。

主要从事纳米递药系统、药物传递新技术、中西药物制剂开发方面的工作。先后主持中国博士后科学基金、国家自然科学基金等项目多项。在药学和纳米医学领域发表SCI论文30余篇。为ACS Appl Mater Interfaces,Int J Pharm,J Drug Targeting,Drug Deliv,AAPS PharmaSciTech等多个SCI期刊的同行评议人。申请发明专利4项，授权1项。参编教材1部。

主要研究方向

1.纳米药物传递系统

2.口服给药及糖尿病纳米医学

3.中西药物制剂开发与评价

承担科研项目

1.基于“药载共济”效应构建桑葛提取物复合硒纳米系统用于糖尿病治疗研究（81673604），国家自然科学基金面上项目，2017.01-2020.12，主持

2.两疏性抗癌药物新载体磷脂化多孔碳纳米球的构建及其体内释药机制研究（81402855），国家自然科学基金青年项目，2015.01 ~ 2017.12，主持

3.胰岛素硒纳米粒的制备及口服降糖作用研究（21617473），暨南大学科研培育与创新基金，2017.01 ~ 2018.12，主持

4.自靶向多孔碳纳米球作为两疏性肿瘤药物递释载体研究（2014M562253），中国博士后科学基金项目，2014.09 ~ 2015.09，主持

代表性论文

1. Qian Xie, Wenji Deng, Xue Yuan, Huan Wang, Zhiguo Ma, Baojian Wu,Xingwang Zhang*. Selenium-functionalized liposomes for systemic delivery of doxorubicin with enhanced pharmacokinetics and anticancer effect.European Journal of Pharmaceutics and Biopharmaceutics. 2018; 122: 87-95.

2. Huijie Xing, Huan Wang, Baojian Wu,Xingwang Zhang*. Lipid nanoparticles for the delivery of active natural medicines.Current Pharmaceutical Design. 2017; doi: 10.2174/1381612824666171128105853.

3. Wenji Deng, Qian Xie, Huan Wang, Zhiguo Ma, Boajian Wu*,Xingwang Zhang*. Selenium nanoparticles as versatile carriers for oral delivery of insulin: insight into the synergic antidiabetic effect and mechanism.Nanomedicine: Nanotechnology, Biology and Medicine. 2017; 13: 1965-1974.

4. Zhongjian Chen, Tianpeng Zhang, Baojian Wu,Xingwang Zhang*. Insights into the therapeutic potential of hypoxia-inducible factor-1α; small interfering RNA in malignant melanoma delivered via folate-decorated cationic liposomes.International Journal of Nanomedicine. 2016; 11:991-1002.

5. Yanghuan Ye, Tianpeng Zhang, Wan Li, Hua Sun, Danyi Lu, Baojian Wu*,Xingwang Zhang*. Glucose-based mesoporous carbon nanospheres as functional carriers for oral delivery of amphiphobic raloxifene: insights into the bioavailability enhancement and lymphatic transport.Pharmaceutical Research. 2016; 33(3): 792-803.

6.Xingwang Zhang, Tianpeng Zhang, Yali Lan, Baojina Wu* and Zhihai Shi*. Nanosuspensions containing oridonin/HP-β-cyclodextrin inclusion complexes for oral bioavailability enhancement via improved dissolution and permeability.AAPS PharmSciTech. 2016; 17(2):400-408.

7.Xingwang Zhang, Dong Dong, Huailing Wang, Zhiguo Ma, Baojian Wu*. Stable knockdown of efflux transporters leads to reduced glucuronidation in UGT1A1-overexpressing HeLa cells: the evidence for glucuronidation-transport interplay.Molecular Pharmaceutics. 2015; 12(4): 1268-78.

8. Wan Li, Tianpeng Zhang, Yanghuan Ye,Xingwang Zhang*, Baojian Wu*. Enhanced bioavailability of tripterine through lipid nanoparticles using broccoli-derived lipids as a new carrier material.International Journal of Pharmaceutics. 2015; 495: 948-955.

9.Xingwang Zhang, Tianpeng Zhang, Yanghuan Ye, Huaqing Chen, Hua Sun, Xiaotong Zhou, Zhiguo Ma, Baojian Wu*. Phospholipid-stabilized mesoporous carbon nanospheres as versatile carriers for systemic delivery of amphiphobic SNX-2112 (a Hsp90 inhibitor) with enhanced antitumor effect.European Journal of Pharmaceutics and Biopharmaceutics. 2015; 94:30-41.

10. Xiaotong Zhou,Xingwang Zhang*, Yanghuan Ye, Tianpeng Zhang, Huan Wang, Zhiguo Ma, and Baojian Wu*. Nanostructured lipid carriers used for oral delivery of oridonin: an effect of ligand modification on absorption.International Journal of Pharmaceutics. 2015; 479: 391-398.

11. Yanghuan Ye,Xingwang Zhang*, Tianpeng Zhang, Huan Wang, and Baojian Wu*. Design and evaluation of injectable niclosamide nanocrystals prepared by wet media milling technique.Drug Development and Industrial Pharmacy. 2015; 41(9):1416-1424.

12.Xingwang Zhang, Yong Zhang, Tianpeng Zhang, Jianping Zhang*, and Baojian Wu*. Significantly enhanced bioavailability of niclosamide through submicron lipid emulsions with or without PEG-lipid: a comparative study.Journal of Microencapsulation. 2015; 32:496-502.

13.Xingwang Zhangand Baojian Wu*. Submicron lipid emulsions-a versatile platform for drug delivery.Current Drug Metabolism. 2015; 16: 211-220.

14.Xingwang Zhang, Jianping Qi, Yi Lu, Xiaoyang Li, Wei He, Wei Wu*. Biotinylated liposomes as potential carriers for oral delivery of insulin.Nanomedicine: Nanotechnology, Biology and medicine. 2014; 10: 167-176.

15.Xingwang Zhangand Wei Wu*. Ligand-mediated active targeting for enhanced oral absorption.Drug Discovery Today. 2014; 19: 898-904.

16.Xingwang Zhang, Tianpeng Zhang, Xiaotong Zhou, Hongming Liu, Hua Sun, Zhiguo Ma, Baojian Wu*. Enhancement of oral bioavailability of tripterine through lipid nanospheres: preparation, characterization, and absorption evaluation.Journal of Pharmaceutical Sciences. 2014; 103: 1711-1719.

17.Xingwang Zhang, Jianping Qi*, Yi Lu, Xiongwei Hu, Wei He, and Wei Wu. Enhanced hypoglycemic effect of biotin-modified liposomes loading insulin: effect of formulation variables, intracellular trafficking, and cytotoxicity.Nanoscale Research Letters. 2014; 9: 185-194.

18.Xingwang Zhang, Huan Wang, Tianpeng Zhang, Xiaotong Zhou, Baojian Wu*. Exploring the potential of self-assembled mixed micelles in enhancing the stability and oral bioavailability of an acid-labile drug.European Journal of Pharmaceutical Sciences. 2014; 62: 301-308.

19.Xingwang Zhang, Huan Wang, Zhiguo Ma, and Baojian Wu*. Effects of pharmaceutical PEGylation on drug metabolism and its clinical concerns.Expert Opinion on Drug Metabolism & Toxicology. 2014; 10(12):1691-1702.

20.Xingwang Zhang, Guijiang Chen, Tianpeng Zhang, Zhiguo Ma, and Baojian Wu*. Effects of PEGylated lipid nanoparticles on the oral absorption of one BCS II drug: a mechanistic investigation.International Journal of Nanomedicine. 2014; 26: 5503-5514.

联系方式：

广州黄埔大道西601号暨南大学药学院325室

Email：zhangxw@jnu.edu.cn